NewAmsterdam Pharma Company (NAMS): Dana dhuwit perusahaan

Logo korporat perusahaan NewAmsterdam Pharma (NAMS)

NewAmsterdam Pharma (NAMS) relies on external contractors for testing and strictly adheres to FDA waste disposal regulations. The current cash reserve level on the GURU.Markets chart demonstrates that the indicator value reaches 0.63. High risks persist due to the lack of profit until the completion of clinical trials for metabolic therapy, rendering the company's cash flows unpredictable.

NAMS - Cadangan dhuwit perusahaan NewAmsterdam Pharma Corp ing rentang 21.06.2023 - 21.11.2026

Rincian analitis perusahaan NewAmsterdam Pharma

- nilai saham lan prakiraan konsensus rega:
Analisis fundamental perusahaan:NAMS newamsterdampharma.com
Produk merek NewAmsterdam Pharma Company N.V.

To find a fundamental balance between the cost and quality of NewAmsterdam Pharma (NAMS) assets, it is essential to analyze the volume of liquid reserves, which currently stands at 0.63. This metric measures the company's ability to cover operating expenses with cash, eliminating the illusion of growth while capital is actually being depleted. Amid stringent FDA regulation and costly clinical trials, the history of cash balance fluctuations confirms the business's financial stability in the face of high barriers to entry.

Pesaing utama

Dana dhuwit perusahaan ascendispharma.com (ASND)|Dhuwit awis perusahaan madrigalpharma.com MDGL|Volume dana dhuwit perusahaan CORT (Corcept Therapeutics Inc.)|Sisa dhuwit perusahaan RYTM|AKRO - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Metsera Inc|MoonLake Immunotherapeutics AG (MLTX) - Dana dhuwit perusahaan|CRNX - Aset likuid perusahaan|SLNO (Soleno Therapeutics Corp) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan Amicus Pharma (FOLD)|Dhuwit awis perusahaan ETNB (89bio Corp)|Aset likuid perusahaan Agios Pharmaceuticals|Structure Pharma - Dhuwit awis perusahaan|MDXG: Dhuwit awis lan setara dhuwit awis perusahaan|RZLT: Dhuwit awis perusahaan|LXRX (Lexicon Pharma) - Dhuwit awis lan setara dhuwit awis perusahaan|MBX: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Altimmune, Inc. (ALT)|Dhuwit awis perusahaan AARD|Dana dhuwit perusahaan SGMT|Volume dana dhuwit perusahaan BIOA|Aset likuid perusahaan Biomea Fusion|Dana dhuwit perusahaan Quince Therapeutics QNCX|Volume dana dhuwit perusahaan Fractyl Health, Inc GUTS|VTVT: Dhuwit awis perusahaan|Cadangan dhuwit perusahaan Agape ATP|PLUR (Pluri) - Dhuwit awis perusahaan|SYBX - Aset likuid perusahaan|Dana dhuwit perusahaan Lipocine Corp|Volume dana dhuwit perusahaan matinasbiopharma.com|Dana dhuwit perusahaan Spruce Biosciences, Inc. (SPRB)|Gunggung dana dhuwit perusahaan GLTO|Carmell Corporation - Dhuwit awis perusahaan|LUMO - Dhuwit awis perusahaan|ONVO - Dana dhuwit perusahaan|Sisa dhuwit perusahaan RDUS (Radius Health)